Published online July 1, 2005
PEDIATRICS Vol. 116 No. 1 July 2005, pp. 61-67 (doi:10.1542/peds.2004-1605)
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Web of Science (10)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Abelson, J. A.
Right arrow Articles by Nielsen, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abelson, J. A.
Right arrow Articles by Nielsen, K.
Related Collections
Right arrow Infectious Disease & Immunity
Right arrowRelated AAP Red Book topics:
Fungal Diseases
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Frequency of Fungemia in Hospitalized Pediatric Inpatients Over 11 Years at a Tertiary Care Institution

Jonathan A. Abelson, BA*, Theodore Moore, MD{ddagger}, David Bruckner, ScD§, Jaime Deville, MD{ddagger} and Karin Nielsen, MD, MPH{ddagger}

* David Geffen School of Medicine
{ddagger} Department of Pediatrics, Mattel Children's Hospital
§ Department of Microbiology, University of California, Los Angeles, California

Objectives. To determine the frequency of bloodstream fungal infections in children who were admitted to our tertiary institution over an 11-year period.

Methods. We conducted a retrospective cohort study of patients who were aged 0 to 21 years, had bloodstream fungal infections, and were admitted to the University of California, Los Angeles from 1991 through 2001. Patients were identified through the microbiology laboratory database. All positive fungal cultures for pediatric inpatients were reviewed. For each fungemic patient, a review of clinical course, cause, and outcome was performed.

Results. Over 11 years, 1124 pediatric inpatients with 3633 positive cultures had evidence of fungal colonization or infection. The mean incidence of positive fungal cultures increased from 105 between 1991 and 1996 to 129 patients per year between 1997 and 2001. Fungal isolates were mainly Candida species (85%) obtained primarily from respiratory (41%) and urine (27%) cultures. Only 7.5% of positive fungal cultures were from blood, although 24490 pediatric admissions prompted 72960 bacterial and fungal blood cultures, at charges of $2.52 million. Of 14592 fungal blood cultures, <2% (n = 272) were positive, involving <1% (n = 97) of patients. The mean rise in number of children with fungemia was significant, from 6.8 between 1991 and 1996 to 13.0 patients per year between 1997 and 2001. Fungemia was associated with a high all-cause mortality rate (46%), particularly in immunocompromised patients (57%). Organisms recovered were primarily Candida species (91%). There was a decline in C albicans and C glabrata fungemia and an increase in C parapsilosis organisms. In 84% of patients, fungal organisms were isolated from both bacterial and fungal blood cultures, and in 74%, the same organism was isolated from additional body sites.

Conclusions. Episodes of fungemia increased significantly over 11 years as compared with a moderate increase in positive fungal cultures and were associated with high all-cause mortality rates. More sensitive assays for early identification of fungal bloodstream infections are warranted.

Key Words: fungal infections children • fungemia pediatrics • nosocomial infections • immunocompromised patients

Abbreviations: UCLA, University of California, Los Angeles

Accepted Oct 27, 2004.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
M. Neely, H. S. Jafri, N. Seibel, K. Knapp, P. C. Adamson, S. K. Bradshaw, K. M. Strohmaier, P. Sun, S. Bi, M. F. Dockendorf, et al.
Pharmacokinetics and Safety of Caspofungin in Older Infants and Toddlers
Antimicrob. Agents Chemother., April 1, 2009; 53(4): 1450 - 1456.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
T. E. Zaoutis, H. S. Jafri, L.-M. Huang, F. Locatelli, A. Barzilai, W. Ebell, W. J. Steinbach, J. Bradley, J. M. Lieberman, C.-C. Hsiao, et al.
A Prospective, Multicenter Study of Caspofungin for the Treatment of Documented Candida or Aspergillus Infections in Pediatric Patients
Pediatrics, March 1, 2009; 123(3): 877 - 884.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. M. Abdel-Rahman, R. F. Jacobs, J. Massarella, R. E. Kauffman, J. S. Bradley, H. C. Kimko, G. L. Kearns, K. Shalayda, C. Curtin, S. D. Maldonado, et al.
Single-Dose Pharmacokinetics of Intravenous Itraconazole and Hydroxypropyl-{beta}-Cyclodextrin in Infants, Children, and Adolescents
Antimicrob. Agents Chemother., August 1, 2007; 51(8): 2668 - 2673.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. A. Soloviev, W. A. Fonzi, R. Sentandreu, E. Pluskota, C. B. Forsyth, S. Yadav, and E. F. Plow
Identification of pH-Regulated Antigen 1 Released from Candida albicans as the Major Ligand for Leukocyte Integrin {alpha}Mbeta2
J. Immunol., February 15, 2007; 178(4): 2038 - 2046.
[Abstract] [Full Text] [PDF]